Completed OBSERVATIONAL NCT03932877

Serum Soluble Endoglin and Matrix Metalloproteinase 14 With Elisa Method in Early/Late-onset Preeclampsia

An Analysis Soluble Endoglin and Matrix Metalloproteinase 14 With Elisa Method in the Diagnosis and Severity of Early/Late-onset Preeclampsia

Sponsor: Cengiz Gokcek Women's and Children's Hospital

Conditions Preeclampsia

Interventions MMP-14 and s-ENG levels

Updated 5 times since 2019 Last updated: Apr 30, 2019 Started: Jan 30, 2018 Primary completion: Nov 30, 2018 Completion: Dec 30, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Preeclampsia and is currently completed. Cengiz Gokcek Women's and Children's Hospital leads this study, which shows 5 recorded versions since 2018 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2025 — Present [monthly]

Completed
Sep 2024 — Sep 2025 [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Jan 2021 — Jul 2024 [monthly]

Completed
Jun 2019 — Jan 2021 [monthly]

Completed

First recorded

Jan 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Cengiz Gokcek Women's and Children's Hospital

Data source: Cengiz Gokcek Women's and Children's Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Gaziantep, Turkey (Türkiye)